These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 37989928)

  • 1. Momelotinib: First Approval.
    Keam SJ
    Drugs; 2023 Dec; 83(18):1709-1715. PubMed ID: 37989928
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Momelotinib in myelofibrosis: JAK1/2 inhibitor with a role in treating and understanding the anemia.
    Winton EF; Kota V
    Future Oncol; 2017 Feb; 13(5):395-407. PubMed ID: 27785927
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase 2 study of momelotinib, a potent JAK1 and JAK2 inhibitor, in patients with polycythemia vera or essential thrombocythemia.
    Verstovsek S; Courby S; Griesshammer M; Mesa RA; Brachmann CB; Kawashima J; Maltzman JD; Shao L; Xin Y; Huang D; Bajel A
    Leuk Res; 2017 Sep; 60():11-17. PubMed ID: 28622623
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Momelotinib for the treatment of myelofibrosis with anemia.
    Tremblay D; Mesa R
    Future Oncol; 2022 Jun; 18(20):2559-2571. PubMed ID: 35603634
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Momelotinib: an emerging treatment for myelofibrosis patients with anemia.
    Chifotides HT; Bose P; Verstovsek S
    J Hematol Oncol; 2022 Jan; 15(1):7. PubMed ID: 35045875
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MOMENTUM: momelotinib vs danazol in patients with myelofibrosis previously treated with JAKi who are symptomatic and anemic.
    Verstovsek S; Chen CC; Egyed M; Ellis M; Fox L; Goh YT; Gupta V; Harrison C; Kiladjian JJ; Lazaroiu MC; Mead A; McLornan D; McMullin MF; Oh ST; Perkins A; Platzbecker U; Scheid C; Vannucchi A; Yoon SS; Kowalski MM; Mesa RA
    Future Oncol; 2021 Apr; 17(12):1449-1458. PubMed ID: 33423550
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinib.
    Bryan JC; Verstovsek S
    Cancer Chemother Pharmacol; 2016 Jun; 77(6):1125-42. PubMed ID: 27017614
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Momelotinib: Mechanism of action, clinical, and translational science.
    Vlasakakis G; McCabe MT; Ho YL; Ferron-Brady G; Martin P; Bentley D; Ellis C; Antonysamy M; Visser SAG
    Clin Transl Sci; 2024 Aug; 17(8):e70018. PubMed ID: 39189872
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Momelotinib inhibits ACVR1/ALK2, decreases hepcidin production, and ameliorates anemia of chronic disease in rodents.
    Asshoff M; Petzer V; Warr MR; Haschka D; Tymoszuk P; Demetz E; Seifert M; Posch W; Nairz M; Maciejewski P; Fowles P; Burns CJ; Smith G; Wagner KU; Weiss G; Whitney JA; Theurl I
    Blood; 2017 Mar; 129(13):1823-1830. PubMed ID: 28188131
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Splenomegaly in myelofibrosis--new options for therapy and the therapeutic potential of Janus kinase 2 inhibitors.
    Randhawa J; Ostojic A; Vrhovac R; Atallah E; Verstovsek S
    J Hematol Oncol; 2012 Aug; 5():43. PubMed ID: 22852872
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pacritinib: First Approval.
    Lamb YN
    Drugs; 2022 May; 82(7):831-838. PubMed ID: 35567653
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differences in presenting features, outcome and prognostic models in patients with primary myelofibrosis and post-polycythemia vera and/or post-essential thrombocythemia myelofibrosis treated with ruxolitinib. New perspective of the MYSEC-PM in a large multicenter study
    Palandri F; Palumbo GA; Iurlo A; Polverelli N; Benevolo G; Breccia M; Abruzzese E; Tiribelli M; Bonifacio M; Tieghi A; Isidori A; Martino B; Sgherza N; D'Adda M; Bergamaschi M; Crugnola M; Cavazzini F; Bosi C; Binotto G; Auteri G; Latagliata R; Ibatici A; Scaffidi L; Penna D; Cattaneo D; Soci F; Trawinska M; Russo D; Cuneo A; Semenzato G; Di Raimondo F; Aversa F; Lemoli RM; Heidel F; Reggiani MLB; Bartoletti D; Cavo M; Catani L; Vianelli N
    Semin Hematol; 2018 Oct; 55(4):248-255. PubMed ID: 30502854
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase 1/2, open-label study evaluating twice-daily administration of momelotinib in myelofibrosis.
    Gupta V; Mesa RA; Deininger MW; Rivera CE; Sirhan S; Brachmann CB; Collins H; Kawashima J; Xin Y; Verstovsek S
    Haematologica; 2017 Jan; 102(1):94-102. PubMed ID: 27634203
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Myelofibrosis: an update on drug therapy in 2016.
    Bose P; Verstovsek S
    Expert Opin Pharmacother; 2016 Dec; 17(18):2375-2389. PubMed ID: 27774820
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emerging drugs for the therapy of primary and post essential thrombocythemia, post polycythemia vera myelofibrosis.
    Mesa RA; Tefferi A
    Expert Opin Emerg Drugs; 2009 Sep; 14(3):471-9. PubMed ID: 19552608
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Momelotinib in myelofibrosis.
    Bruzzese A; Martino EA; Labanca C; Mendicino F; Lucia E; Olivito V; Zimbo A; Fragliasso V; Neri A; Morabito F; Vigna E; Gentile M
    Expert Opin Pharmacother; 2024 Apr; 25(5):521-528. PubMed ID: 38623844
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Amelioration of Myelofibrosis with Thrombocytopenia by a JAK1/2 Inhibitor, Ruxolitinib, in a Post-polycythemia Vera Myelofibrosis Patient with a JAK2 Exon 12 Mutation.
    Ikeda K; Ueda K; Sano T; Ogawa K; Ikezoe T; Hashimoto Y; Morishita S; Komatsu N; Ohto H; Takeishi Y
    Intern Med; 2017; 56(13):1705-1710. PubMed ID: 28674362
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis.
    Pardanani A; Laborde RR; Lasho TL; Finke C; Begna K; Al-Kali A; Hogan WJ; Litzow MR; Leontovich A; Kowalski M; Tefferi A
    Leukemia; 2013 Jun; 27(6):1322-7. PubMed ID: 23459451
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ACVR1/JAK1/JAK2 inhibitor momelotinib reverses transfusion dependency and suppresses hepcidin in myelofibrosis phase 2 trial.
    Oh ST; Talpaz M; Gerds AT; Gupta V; Verstovsek S; Mesa R; Miller CB; Rivera CE; Fleischman AG; Goel S; Heaney ML; O'Connell C; Arcasoy MO; Zhang Y; Kawashima J; Ganz T; Kowalski M; Brachmann CB
    Blood Adv; 2020 Sep; 4(18):4282-4291. PubMed ID: 32915978
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase II trial of tipifarnib in myelofibrosis: primary, post-polycythemia vera and post-essential thrombocythemia.
    Mesa RA; Camoriano JK; Geyer SM; Wu W; Kaufmann SH; Rivera CE; Erlichman C; Wright J; Pardanani A; Lasho T; Finke C; Li CY; Tefferi A
    Leukemia; 2007 Sep; 21(9):1964-70. PubMed ID: 17581608
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.